What place do BRCA1 and BRCA2 have in the hereditary risk of ovarian cancer?;Quelle place tiennent les gènes BRCA1 et BRCA2 dans les risques héréditaires de cancer de l'ovaire?

Oncologie

Volumn 7, Issue 7, 2005, Pages 526-530

  Uhrhammer, N ^a   Bornes, S ^a   Bignon, Y J ^a  

^a CENTRE JEAN PERRIN   (France)

Author keywords

BRCA; Cancer; Heredity; Ovary

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; GENE PRODUCT;

ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SURGERY; ENVIRONMENTAL FACTOR; FAMILIAL CANCER; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEREDITY; HETEROZYGOTE; HUMAN; MOLECULAR DYNAMICS; MUTAGENESIS; ONCOGENE; OVARY CANCER; POSTMENOPAUSE;

EID: 30444445267     PISSN: 12923818     EISSN: 17652839     Source Type: Journal    
DOI: 10.1007/s10269-005-0283-0     Document Type: Article

References (32)

1. Antoniou A, Pharoah PD, Narod S, et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72 (5): 1117-30
2. Fuks F, Milner J, Kouzarides T (1998) BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene 17 (19): 2531-4
3. Galkin VE, Esashi F, Yu X, et al. (2005) BRCA2 BRC motifs bind RAD51-DNA filaments. Proc Natl Acad Sci USA 102 (24): 8537-42
4. Gayther SA, Ponder BA (1997) Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing. Mol Med Today 3 (4): 168-74
5. Hall HI, Jamison P, Weir HK (2001) Second primary ovarian cancer among women diagnosed previously with cancer. Cancer Epidemiol Biomarkers Prev 10 (9): 995-9
6. Hashizume R, Fukuda M, Maeda I, et al. (2001) The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 276 (18): 14537-40
7. Hemminki K, Granstrom C (2003) Familial breast cancer: scope for more susceptibility genes? Breast Cancer Res Treat 82 (1): 17-22
8. Lakhani SR, Manek S, Penault-Llorca F, et al. (2004) Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 10 (7): 2473-81
9. Lauffart B, Vaughan MM, Eddy R, et al. (2005) Aberrations of TACC1 and TACC3 are associated with ovarian cancer. BMC Womens Health 5: 8
10. Lotti LV, Ottini L, D'Amico C, et al. (2002) Subcellular localization of the BRCA1 gene product in mitotic cells. Genes Chromosomes Cancer 35 (3): 193-203
11. Lynch ED, Ostermeyer EA, Lee MK, et al. (1997) Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet 61 (6): 1254-60
12. Maresco DL, Arnold PH, Sonoda Y, et al. (1999) The APC I1307K allele and BRCA-associated ovarian cancer risk. Am J Hum Genet 64 (4): 1228-30
13. Marmorstein LY, Ouchi T, Aaronson SA (1998) The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci USA 95 (23): 13869-74
14. Miki Y, Swensen J, Shattuck-Eidens D, et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 (5182): 66-71
15. Milner J, Fuks F, Hughes-Davies L, Kouzarides T (2000) The BRCA2 activation domain associates with and is phosphorylated by a cellular protein kinase. Oncogene 19 (38): 4441-5
16. Moynahan ME, Chiu JW, Koller BH, Jasin M (1999) BRCA1 controls homology-directed DNA repair. Mol Cell 4 (4): 511-8
17. Narod SA (2002) Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2 (2): 113-23
18. Obata K, Morland SJ, Watson RH, et al. (1998) Campbell, Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58 (10): 2095-7
19. Paull TT, Rogakou EP, Yamazaki V, et al. (2000) A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 10 (15): 886-95
20. Phelan CM, Rebbeck TR, Weber BL, et al. (1996) Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet 12 (3): 309-11
21. Rebbeck TR, Lynch HT, Neuhausen SL, et al. (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 (21): 1616-22
22. Rhei E, Bogomolniy F, Federici MG, et al. (1998) Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res 58 (15): 3193-6
23. Rodriguez-Lopez R, Osorio A, Ribas G, et al. (2004) The variant E233G of the RAD51D gene could be a low-penetrance allele in high-risk breast cancer families without BRCA1/2 mutations. Int J Cancer 110 (6): 845-9
24. Salazar H, Godwin AK, Daly MB, et al. (1996) Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 88 (24): 1810-20
25. Scully R, Anderson SF, Chao DM, et al. (1997) BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci USA 94 (11): 5605-10
26. Scully R, Livingston DM (2000) In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408 (6811): 429-32
27. Wong AS, Auersperg N (2003) Ovarian surface epithelium: family history and early events in ovarian cancer. Reprod Biol Endocrinol 1: 70
28. Wooster R, Bignell G, Lancaster J, et al. (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378 (6559): 789-92
29. Xia F, Taghian DG, DeFrank JS, et al. (2001) Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc Natl Acad Sci USA 98 (15): 8644-9
30. Yarden RI, Pardo-Reoyo S, Sgagias M, et al. (2002) BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 30 (3): 285-9
31. Zheng L, Pan H, Li S, et al. (2000) Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. Mol Cell 6 (4): 757-68
32. Zhong Q, Chen CF, Li S, et al. (1999) Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 285 (5428): 747-50